Healthspan & clinical ageing
Function, resilience and the outcomes that determine how well people live as they age.
Find the question you want to explore
Focus on outcomes people can experience: mobility, independence, resilience and care. Distinguish a laboratory marker from a meaningful change in day-to-day function.
14 topic dossiers connect research, trials, universities, funding and patent activity. Coverage is still growing; numbers describe the indexed records, not all evidence worldwide.
Frailty
How frailty is measured, prevented, and treated.
Open evidence dossier →Cancer and ageing
Shared mechanisms and trade-offs at the intersection of cancer and ageing.
Open evidence dossier →Multimorbidity
Coexisting chronic conditions, shared drivers, and healthspan.
Open evidence dossier →Physiological resilience
Recovery from infection, surgery, stress, and other health challenges.
Open evidence dossier →Falls prevention
Interventions and risk factors related to preventing falls in older people.
Open evidence dossier →Mobility disability
Onset, prevention and recovery of limitations in movement and community mobility.
Open evidence dossier →Activities of daily living
Ability to perform essential daily tasks as a core healthy-ageing outcome.
Open evidence dossier →Disability-free survival
Years lived without major physical or cognitive disability.
Open evidence dossier →Compression of morbidity
Whether disease and disability can be delayed toward the end of life.
Open evidence dossier →Chronic pain and ageing
Persistent pain, function and treatment challenges across later life.
Open evidence dossier →Mental health and ageing
Emotional wellbeing, psychiatric symptoms and resilience in later life.
Open evidence dossier →Polypharmacy
Use of multiple medicines, interactions and outcomes in older adults.
Open evidence dossier →Deprescribing
Planned medication reduction to improve safety and function in later life.
Open evidence dossier →Vaccination in older adults
Vaccine response, effectiveness and strategies to overcome immunosenescence.
Open evidence dossier →